- Home
- NRXP vs IXHL Comparison
NRXP vs IXHL Comparison
Compare NRXP & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXP | IXHL |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 49.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NRXP | IXHL |
|---|---|---|
| Price | $2.35 | $0.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $30.50 | N/A |
| AVG Volume (30 Days) | 430.4K | ★ 24.0M |
| Earning Date | 11-17-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $242,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $643.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.15 | $0.08 |
| 52 Week High | $6.01 | $2.25 |
Technical Indicators
Market Signals| Indicator | NRXP | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 55.34 |
| Support Level | $2.22 | $0.35 |
| Resistance Level | $2.51 | $0.50 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 66.67 | 59.53 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.